Abstract:Apoptosis as a novel target for cancer chemotherapy has generated an intense demand for new apoptosis-inducing agents. The newly revealed role of protein families involved in the apoptosis pathway, and resistance to cytotoxic therapies have opened new avenues for the development of novel anticancer strategies. We have established a novel strategy to rapidly obtain protein-targeted, instead of conventional DNA-targeted, apoptosis inducers as antitumor leads. First, a novel organic non-DNA intercalative compound S1 (8-oxo-3-thiomorpholin-4-yl-8H-acenaphto[1,2-b]pyrrole-9-carbonitrile, M-W = 331) was found with an IC50 of 10(-7)-10(-8) mu M against diverse cancer cell lines. Further biological evaluation demonstrated that it was an apoptosis-inducer both in vivo and in vitro. The treatment of hydroperitoneum hepatoma cells (H22 cell line) with S1 at various concentrations (from 0.01 to 10 mu M) for 24 h triggered these cells to enter the apoptosis process. The antitumor efficiency was also tested in the H22 xenotransplant models in mice. At a dosage of 0.3 mg kg(-1), S1 exhibited significant antitumor activity with a much longer survival time, a decrease in tumor size, and increased apoptosis cells in tumor tissue. More importantly, studies of the molecular mechanism of apoptosis induction by S1 revealed that S1 inactivated the Bcl-2 protein by binding to it, depolarizing the mitochondrial membrane, and then activating caspase 9, followed by caspase 3. Finally, structure-based virtual modification was performed by computer modeling. As a result, a derivative, S2 (8-oxo-3-[(thienylmethyl)amino]-8H-acenaphtho[1,2-b]pyrrole-9-carbonitrile, M-W = 341) was identified that possessed a lower binding energy to Bcl-2, and demonstrated better antitumor potency, even on the Bcl-2-overexpressing human acute myeloid leukemia (HL-60) cells (IC50 = 1.3 mu M) in vitro. S1 and S2 are the well-defined Bcl-2 inhibitors that give us a promising platform for the development of new therapeutic agents.

Novel X-linked Inhibitor of Apoptosis Protein Inhibitors As Probes of Apoptosis in Biology and Medicine

Development of XIAP Antagonists Based on De Novo 8,5-Fused Bicyclic Lactams.

Design, Synthesis, And Interaction Study Of Quinazoline-2(1h)-Thione Derivatives As Novel Potential Bcl-X(L) Inhibitors

Distinct Domains for Anti- and Pro-apoptotic Activities of IEX-1

Theoretical Studies on the Interactions of XIAP-BIR3 Domain with Bicyclic and Tricyclic Core Monovalent Smac Mimetics

Structure–activity Based Study of the Smac-binding Pocket Within the BIR3 Domain of XIAP

XIAP as a Target of New Small Organic Natural Molecules Inducing Human Cancer Cell Death

Structure based pharmacophore modeling, virtual screening, molecular docking and ADMET approaches for identification of natural anti-cancer agents targeting XIAP protein

Design, in silico evaluation, and in vitro verification of new bivalent Smac mimetics with pro-apoptotic activity

Development and Optimization of A Binding Assay for the Xiap Bir3 Domain Using Fluorescence Polarization

Potent and selective small-molecule inhibitors of cIAP1/2 proteins reveal that the binding of Smac mimetics to XIAP BIR3 is not required for their effective induction of cell death in tumor cells.

Towards New Anti‐inflammatory Agents: Design, Synthesis and Evaluation of Molecules Targeting XIAP‐BIR2

Novel Bcl‐2 Inhibitors: Discovery and Mechanism Study of Small Organic Apoptosis‐Inducing Agents

Bivalent SMAC Mimetics for Treating Cancer by Antagonizing Inhibitor of Apoptosis Proteins

Discovery of Embelin As a Cell-Permeable, Small-Molecular Weight Inhibitor of XIAP Through Structure-Based Computational Screening of a Traditional Herbal Medicine Three-Dimensional Structure Database

Advances in the Research of Inhibitor-of-Apoptosis Protein XIAP

Inhibitor of Apoptosis Protein (IAP) Antagonists in Anticancer Agent Discovery: Current Status and Perspectives.

Study on the Interactions of Smac Mimetics with Xiap-Bir3 Domain by Docking and Molecular Dynamics Simulations

Design and synthesis of a simplified inhibitor for XIAP-BIR3 domain

Design, Synthesis And Structure-Activity Relationship Studies Of Novel Survivin Inhibitors With Potent Anti-Proliferative Properties

Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ